期刊
FEBS JOURNAL
卷 287, 期 12, 页码 2418-2427出版社
WILEY
DOI: 10.1111/febs.15264
关键词
dasatinib; fisetin; Geroscience Hypothesis; MAD cells; navitoclax; quercetin; SASP; SCAPs; senolytics
资金
- NIA NIH HHS [R56 AG061414, P01 AG062413, R37 AG013925, R33 AG061456] Funding Source: Medline
Senescent cells accumulate with aging and at etiological sites of multiple diseases, including those accounting for most morbidity, mortality, and health costs. Senescent cells do not replicate, can release factors that cause tissue dysfunction, and yet remain viable. The discovery of senolytic drugs, agents that selectively eliminate senescent cells, created a new route for alleviating age-related dysfunction and diseases. As anticipated for agents targeting fundamental aging mechanisms that are 'root cause' contributors to multiple disorders, potential applications of senolytics are protean. We review the discovery of senolytics, strategies for translation into clinical application, and promising early signals from clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据